WeVote
Log In

Bill

Bill

SB 463

Requiring Bureau for Public Health to test for mucopolysaccharidosis type 1

2026 Regular Session

West Virginia mandates newborn screening for mucopolysaccharidosis type 1 to enable early detection and treatment of this rare genetic disorder affecting metabolic function.

0
WeVote Research Nonpartisan
Bill Summary · SB 463

Legislative bill overview

SB 463 mandates that West Virginia's Bureau for Public Health include mucopolysaccharidosis type 1 (MPS I) screening in its newborn screening program. MPS I is a rare genetic disorder where the body cannot break down certain complex sugars, leading to progressive organ damage and severe health complications if undetected. The bill requires healthcare providers to test all newborns for this condition as part of standard screening protocols.

Why is this important

Early detection of MPS I through newborn screening enables prompt medical intervention—including enzyme replacement therapy or gene therapy—that can significantly slow disease progression and improve quality of life. Currently, many cases go undiagnosed until symptoms become severe, at which point irreversible organ damage may have occurred. Adding MPS I to mandatory screening expands access to early intervention across the entire state population.

Potential points of contention

  • Cost implications: Expanding newborn screening programs increases laboratory testing expenses; the bill does not specify funding sources or cost estimates for implementation
  • Rare disease prioritization: MPS I affects approximately 1 in 100,000-150,000 births; some may question whether resources should prioritize screening for more common conditions
  • Treatment access gap: Screening without guaranteed access to expensive treatments (enzyme replacement therapy can cost $100,000+ annually) may create anxiety without practical benefit for some families

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.